Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Executive Summary
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.
You may also be interested in...
Mylan Clears Runway For US Herceptin Biosimilar Launch
The generic drug manufacturer is poised to be first to market with a biosimilar version of Roche’s blockbuster breast cancer therapy after reaching a license agreement. The date of a potential launch remains confidential.
Mylan Clears Runway For US Herceptin Biosimilar Launch
The generic drug manufacturer is poised to be first to market with a biosimilar version of Roche’s blockbuster breast cancer therapy after reaching a license agreement. The date of a potential launch remains confidential.
Buoyant Biocon Bullish On US Biosimilar Interchangeability
Ahead of an expected FDA review of its biosimilar trastuzumab later this year, the chair of major Indian biologics company Biocon is positive over the still evolving area of biosimilar interchangeability, saying new US draft guidance is “very welcome.”